East Coast Institute for Research .
Welcome,         Profile    Billing    Logout  
 5 Trials 
31 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Budoff, Matthew
EKSTROM, NCT06342609: Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease

Completed
4
84
US
Colchicine 0.5 MG, Mitigare, Colcrys
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Coronary Artery Disease
09/24
09/24
WARRIOR, NCT03417388: Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD

Active, not recruiting
4
2476
US
High dose potent statin, atorvastatin or rosuvastatin, ACE-I (lisinopril) or ARB (losartan), ACE-I or ARB, Aspirin, Lifestyle Counseling, PACE Lifestyle Intervention, Quality of Life Questionnaires, QOL
University of Florida, United States Department of Defense
Coronary Artery Disease
02/25
09/25
T-PLAQUE, NCT05708859: Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT

Recruiting
4
120
US
Tirzepatide, Mounjaro, Placebo
Matthew J. Budoff, Eli Lilly and Company
Type II Diabetes, Atherosclerosis
12/25
05/26
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
V-PLAQUE, NCT05360446: Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

Active, not recruiting
3
608
Europe, Canada, Japan, US, RoW
Inclisiran sodium 300 mg, Placebo
Novartis Pharmaceuticals
Coronary Artery Disease
01/27
01/27
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Active, not recruiting
3
17004
Europe, Canada, Japan, US, RoW
Inclisiran sodium 300 mg, Placebo
Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
10/27
10/27
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
Keto-CTA, NCT05733325: Diet-induced Elevations in LDL-C and Progression of Atherosclerosis

Completed
N/A
100
US
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Citizen Science Foundation
Hypercholesterolemia
02/24
02/24
Knowles, Joshua W
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
CASCADE-FH, NCT01960244: Study of Awareness and Detection of Familial Hypercholesterolemia

Recruiting
N/A
5000
US
The Familial Hypercholesterolemia Foundation
Hypercholesterolemia
12/25
12/25
Audish, Hanid
CHALLENGE-MIG, NCT05127486: A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine

Checkmark Enrollment initiated in combination with Emgality for episodic migraine
Nov 2021 - Nov 2021: Enrollment initiated in combination with Emgality for episodic migraine
Completed
4
580
US
Galcanezumab, LY2951742, Rimegepant, Placebo
Eli Lilly and Company
Migraine, Episodic Migraine
05/23
05/23
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
QWINT-1, NCT05662332: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed
3
795
US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, T2D
07/24
07/24
TRIUMPH-5, NCT06662383: A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

Recruiting
3
800
Europe, US, RoW
Retatrutide, LY3437943, Tirzepatide, LY3298176
Eli Lilly and Company
Obesity
04/27
04/27
SURMOUNT-5, NCT05822830: A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

Completed
3
751
US
Tirzepatide, LY3298176, Semaglutide
Eli Lilly and Company
Obesity, Overweight
11/24
11/24
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
1576
Japan, US, RoW
Orforglipron, LY3502970, Semaglutide
Eli Lilly and Company
Type 2 Diabetes
09/25
09/25
NCT06047548: A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting
3
400
US
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Overweight, Obesity
05/26
05/26
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
NCT04809376: Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain

Active, not recruiting
2/3
602
US, RoW
Pentosan Polysulfate Sodium twice weekly, PPS twice weekly, Placebo (Sodium Chloride Injection, 0.9%), Placebo, Pentosan Polysulfate Sodium Fixed Dose, Fixed Dose, Pentosan Polysulfate Sodium once weekly, PPS once weekly
Paradigm Biopharmaceuticals USA (INC)
Osteoarthritis, Knee
10/24
01/25
Siu, Brian
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting
3
2196
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
Gonzalez, Stephanie
NCT06267560: Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD

Recruiting
3
400
US
TQJ230, pelacarsen, Placebo
Novartis Pharmaceuticals
Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
03/27
03/27
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Active, not recruiting
N/A
44467
US
Guardant Health, Inc., Premier Research Group plc
Colorectal Cancer
03/24
12/25
Pierpont, Brien
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Active, not recruiting
3
17004
Europe, Canada, Japan, US, RoW
Inclisiran sodium 300 mg, Placebo
Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
10/27
10/27
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
SONAWALA, MEHUL SHAILESH
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting
3
2196
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
Kupser, Andrea
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
Jurgens, Paul
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
Ghoto, Ayesha
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Budoff, Matthew
EKSTROM, NCT06342609: Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease

Completed
4
84
US
Colchicine 0.5 MG, Mitigare, Colcrys
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Coronary Artery Disease
09/24
09/24
WARRIOR, NCT03417388: Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD

Active, not recruiting
4
2476
US
High dose potent statin, atorvastatin or rosuvastatin, ACE-I (lisinopril) or ARB (losartan), ACE-I or ARB, Aspirin, Lifestyle Counseling, PACE Lifestyle Intervention, Quality of Life Questionnaires, QOL
University of Florida, United States Department of Defense
Coronary Artery Disease
02/25
09/25
T-PLAQUE, NCT05708859: Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT

Recruiting
4
120
US
Tirzepatide, Mounjaro, Placebo
Matthew J. Budoff, Eli Lilly and Company
Type II Diabetes, Atherosclerosis
12/25
05/26
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
V-PLAQUE, NCT05360446: Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

Active, not recruiting
3
608
Europe, Canada, Japan, US, RoW
Inclisiran sodium 300 mg, Placebo
Novartis Pharmaceuticals
Coronary Artery Disease
01/27
01/27
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Active, not recruiting
3
17004
Europe, Canada, Japan, US, RoW
Inclisiran sodium 300 mg, Placebo
Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
10/27
10/27
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
Keto-CTA, NCT05733325: Diet-induced Elevations in LDL-C and Progression of Atherosclerosis

Completed
N/A
100
US
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Citizen Science Foundation
Hypercholesterolemia
02/24
02/24
Knowles, Joshua W
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
CASCADE-FH, NCT01960244: Study of Awareness and Detection of Familial Hypercholesterolemia

Recruiting
N/A
5000
US
The Familial Hypercholesterolemia Foundation
Hypercholesterolemia
12/25
12/25
Audish, Hanid
CHALLENGE-MIG, NCT05127486: A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine

Checkmark Enrollment initiated in combination with Emgality for episodic migraine
Nov 2021 - Nov 2021: Enrollment initiated in combination with Emgality for episodic migraine
Completed
4
580
US
Galcanezumab, LY2951742, Rimegepant, Placebo
Eli Lilly and Company
Migraine, Episodic Migraine
05/23
05/23
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
QWINT-1, NCT05662332: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed
3
795
US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, T2D
07/24
07/24
TRIUMPH-5, NCT06662383: A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

Recruiting
3
800
Europe, US, RoW
Retatrutide, LY3437943, Tirzepatide, LY3298176
Eli Lilly and Company
Obesity
04/27
04/27
SURMOUNT-5, NCT05822830: A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

Completed
3
751
US
Tirzepatide, LY3298176, Semaglutide
Eli Lilly and Company
Obesity, Overweight
11/24
11/24
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
1576
Japan, US, RoW
Orforglipron, LY3502970, Semaglutide
Eli Lilly and Company
Type 2 Diabetes
09/25
09/25
NCT06047548: A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting
3
400
US
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Overweight, Obesity
05/26
05/26
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
NCT04809376: Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain

Active, not recruiting
2/3
602
US, RoW
Pentosan Polysulfate Sodium twice weekly, PPS twice weekly, Placebo (Sodium Chloride Injection, 0.9%), Placebo, Pentosan Polysulfate Sodium Fixed Dose, Fixed Dose, Pentosan Polysulfate Sodium once weekly, PPS once weekly
Paradigm Biopharmaceuticals USA (INC)
Osteoarthritis, Knee
10/24
01/25
Siu, Brian
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting
3
2196
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
Gonzalez, Stephanie
NCT06267560: Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD

Recruiting
3
400
US
TQJ230, pelacarsen, Placebo
Novartis Pharmaceuticals
Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
03/27
03/27
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Active, not recruiting
N/A
44467
US
Guardant Health, Inc., Premier Research Group plc
Colorectal Cancer
03/24
12/25
Pierpont, Brien
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Active, not recruiting
3
17004
Europe, Canada, Japan, US, RoW
Inclisiran sodium 300 mg, Placebo
Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
10/27
10/27
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
SONAWALA, MEHUL SHAILESH
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting
3
2196
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
Kupser, Andrea
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
Jurgens, Paul
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
Ghoto, Ayesha
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29

Download Options